WARNReviewer 1· 55% conf
The investigational product, organsims, primers, and analysis software are identified with versions, and the HLO RNA-seq is deposited, but cell-line/organoid authentication and mycoplasma testing are not reported, and antibody details are largely absent.
Evidence
paraphrase[Results, LXR inverse agonists lower TG and cholesterol]
“Information on these compounds is available in patent US11970484B2 (ref. ; Supplementary Fig.).”direct quote[Methods, Statistical analyses / bioinformatics]
“PK parameters were estimated via noncompartmental methods using Pheonix WinNonlin 6.2.1 and 8.3.4 (Certara).”absence[Methods, Preclinical studies]
Mycoplasma testing and cell-line authentication are not reported.PASSReviewer 2· 80% conf
The investigational product (TLC-2716) is named with doses and route, analysis software is identified with versions, and key data (HLO RNA-seq) are deposited under an accession; primer sequences are provided in supplementary material.
Evidence
direct quote[Abstract / Methods, Study design]
“TLC-2716 0.5, 2, 6 or 12 mg (eight participants per dose) orally once daily for 14 days”direct quote[Methods, Phase 1 clinical trial]
“PK parameters were estimated via noncompartmental methods using Pheonix WinNonlin 6.2.1 and 8.3.4 (Certara).”direct quote[Data availability]
“The HLO RNA-sequencing data are available under GEO number GSE299888”FAILReviewer 3· 75% conf
Key biological resources are inadequately identified; only software tools are fully reported, while cell line authentication, mycoplasma testing, and reagent identification are lacking.
Evidence
absence[Methods, Human liver organoids]
Cell line authentication is not reported for HLOs.absence[Methods, Cell culture]
Mycoplasma testing is not mentioned.direct quote[Methods, Statistical analyses]
“PK parameters were estimated via noncompartmental methods using Pheonix WinNonlin 6.2.1 and 8.3.4 (Certara).”